OGNOrganon & Co.
Is the business good?
The checks split: nothing decisive, though returns that lean on debt.
Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.
Leverage-amplified, a high assets-to-equity ratio does much of the work. ROE 32% = margin × turnover × leverage.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is OGN?
Organon & Co. keeps 3.4% of every revenue dollar as profit after everything, against 18% for the median Drug Manufacturers - General name.
Net margin · Drug Manufacturers - General median 18% · 12 months to Q2 2026
- Share count, year on year
- +4.0%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 5.8%
R&D as % of revenue
- Gross margin
- 53%
Gross margin
Details›
- Gross margin12 months to Q2 2026
- 53%
- Net margin12 months to Q2 2026
- 3.4%
- Free cash flow margin
- 9.3%
- R&D as % of revenue
- 5.8%
- Revenue, trailing twelve months
- $6.13B
- Free cash flow, trailing twelve months
- $567M
- Net income, trailing twelve months
- $209M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, General
Ranks #4 of 7 by RyuScore